Study: GSK's Avodart significantly reduces prostate cancer risk

04/27/2009 |

A large clinical study showed that, after four years of observation, the risk of all biopsy-detectable prostate cancer was 23% lower in male patients given GlaxoSmithKline's Avodart compared with those who received placebo. The trial, which focused on 8,100 men ages 50 to 75 with high levels of prostate-specific antigen, could boost GSK's chances of obtaining approval for Avodart's expanded use.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA